Anticancer efficacy of a novel propofol–linoleic acid-loaded escheriosomal formulation against murine hepatocellular carcinoma. (August 2013)

• Record Type: Journal Article
• Authors: Khan, Azmat Ali; Jabeen, Mumtaz; Khan, Aijaz Ahmed; Owais, Mohammad
• Is Part Of: Nanomedicine. Volume 8:Number 8(2013)
• Page Start: 1281
• Page End: 1294
• Publication Date: 2013-08
• Subjects: anticancer -- apoptosis -- escheriosome -- hepatocellular carcinoma -- linoleic acid -- propofol; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm.12.166
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: The preparation and characterization of a novel escheriosomal nanoparticle formulation of a potent anticancer conjugate, 2, 6-diisopropylphenol-linoleic acid (2, 6P–LA), and evaluation of its anticancer efficacy against diethyl nitrosamine-induced hepatocellular carcinoma (HCC) in BALB/c mice.Materials & methods: Escheriosomized 2, 6P–LA nanoparticles were characterized for size, zeta-potential, entrapment efficiency, release kinetics and in vivo toxicity. Their anticancer potential was evaluated on the basis of survival, DNA fragmentation, caspase-3 activation, western blot analysis of apoptotic factors and histopathological changes in hepatocytes of treated animals.Results: The escheriosomized 2, 6P–LA nanoparticles exhibited low toxicity, biocompatibility and bioavailability. As revealed by apoptosis induction, survival rate, expression profiles of Bax, Bcl-2 and caspase-9, escheriosomized 2, 6P–LA nanoparticles were more effective in the treatment of HCC than the free form of 2, 6P–LA in experimental animals.Conclusion: 2, 6P–LA-bearing escheriosome nanoparticles are effective in suppressing HCC in mice. Original submitted 17 January 2012; Revised submitted 27 August 2012; Published online 14 January 2013